Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alzamend Neuro, Inc. (ALZN : NSDQ)
 
 • Company Description   
Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.92 Daily Weekly Monthly
20 Day Moving Average: 935,110 shares
Shares Outstanding: 90.10 (millions)
Market Capitalization: $82.44 (millions)
Beta:
52 Week High: $33.55
52 Week Low: $0.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.14% 10.21%
12 Week -22.46% -14.76%
Year To Date -51.84% -41.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3500 LENOX RD NE SUITE 1500
-
ATLANTA,GA 30326
USA
ph: 844-722-6303
fax: -
None http://www.alzamend.com
 
 • General Corporate Information   
Officers
Stephan Jackman - Chief Executive Officer and Director
William B. Horne - Chairman of the Board
Lien T. Escalona - Chief Financial Officer
Henry C.W. Nisser - Executive Vice President; General Counsel and Dire
Mark Gustafson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 02262M308
SIC: 2834
Fiscal Year
Fiscal Year End: April
Last Reported Quarter: 01/01/22
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 90.10
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $82.44 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.80
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 25.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/22 - -
01/31/22 - -80.23
10/31/21 - -92.67
ROA
04/30/22 - -
01/31/22 - -72.81
10/31/21 - -82.25
Current Ratio
04/30/22 - -
01/31/22 - 26.61
10/31/21 - 9.83
Quick Ratio
04/30/22 - -
01/31/22 - 26.61
10/31/21 - 9.83
Operating Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Net Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Pre-Tax Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Book Value
04/30/22 - -
01/31/22 - 0.13
10/31/21 - 0.15
Inventory Turnover
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Equity
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
Debt-to-Capital
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
 

Powered by Zacks Investment Research ©